AstraZeneca applauds the Senate for passing the Food and Drug Administration (FDA) Safety and Innovation Act of 2012. The Senate passed the FDA bill by a vote of 92-4. The House recently passed similar legislation.
The bill allows the FDA to collect fees from biopharmaceutical companies to help pay for the regulatory review process of medicines and biological products.
Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement yesterday:
“Today’s Senate passage of S. 3187, the Food and Drug Administration (FDA) Safety and Innovation Act of 2012, is the culmination of a multi-year effort on the part of biopharmaceutical companies, FDA, Congress, and stakeholders that featured unprecedented collaboration, public input, and bipartisanship.”
“…The final bill will enhance the efficiency of FDA’s human drug review program, and will help bring safe, effective, and innovative medicines to patients in a timely manner.”
AstraZeneca hopes that the resulting legislation will lead to a more efficient, predictable, transparent and well coordinated drug review process within the FDA while strengthening the scientific base at the agency, supporting patient safety and promoting innovation.
The bill will now move on to President Obama.